
Sign up to save your podcasts
Or


In which Aaron speaks with Alex Chavez, MD-PhD about antiviral drug development. They discuss chemical strategies for protease inhibitor development and the details and rationale of a novel assay that allows for early validation of candidate drugs. Additionally Alex discusses newer collaborations he is engaged in to build cellular resistance to damaging radiation.
By Columbia Biotech Society5
44 ratings
In which Aaron speaks with Alex Chavez, MD-PhD about antiviral drug development. They discuss chemical strategies for protease inhibitor development and the details and rationale of a novel assay that allows for early validation of candidate drugs. Additionally Alex discusses newer collaborations he is engaged in to build cellular resistance to damaging radiation.

43,528 Listeners

766 Listeners

12,237 Listeners

821 Listeners

87,529 Listeners

111,948 Listeners

56,508 Listeners

9,532 Listeners

5,201 Listeners

4,802 Listeners

6,564 Listeners

85 Listeners

5,530 Listeners

29,207 Listeners

15,950 Listeners